This notion that the prothrombotic state of gliomas is associated with poor outcome was reinforced by the finding that mutant IDH1 confers potent antithrombotic properties that prevent patients with IDH1-mutated gliomas from experiencing venous thromboembolism, intratumoral thrombosis, and tumor necrosis (29). This evidence concerns the gene IDH1 and venous thromboembolism.